Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 843

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth

Khandwala, Hasnain M., McCutcheon, Ian E., Flyvbjerg, Allan, Friend, Keith E. · 2000 · Endocrine Reviews

Abstract

Several decades of basic and clinical research have demonstrated that there is an association between the insulin-like growth factors (IGFs) and neoplasia. We begin with a brief discussion of the function and regulation of expression of the IGFs, their receptors and the IGF-binding proteins (IGFBPs). A number of investigational interventional strategies targeting the GH or IGFs are then reviewed. Finally, we have assembled the available scientific knowledge about this relationship for each of the major tumor types. The tumors have been grouped together by organ system and for each of the major tumors, various key elements of the relationship between IGFs and tumor growth are discussed. Specifically these include the presence or absence of autocrine IGF-I and IGF-II production; presence or absence of IGF-I and IGF-II receptor expression; the expression and functions of the IGFBPs; in vitro and in vivo experiments involving therapeutic interventions; and available results from clinical trials evaluating the effect of GH/IGF axis down-regulation in various malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/edrv.21.3.0399

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 120

  1. O’Gorman, 1999, Decreased insulin-like growth factor-II/mannose-6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells., Cancer Res, 59, 5692
  2. Hofbauer, 1995, Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine., Eur J Endocrinol, 132, 605, 10.1530/eje.0.1320605 · doi:10.1530/eje.0.1320605
  3. Kim, 1998, Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors., Am J Med Genet, 80, 391, 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO;2-H · doi:10.1002/(sici)1096-8628(19981204)80:4<391::aid-ajmg16>3.0.co;2-h
  4. Nonomura, 1997, Altered imprinting of the H19 and insulin-like growth factor II genes in testicular tumors., J Urol, 157, 1977, 10.1016/S0022-5347(01)64913-9 · doi:10.1016/s0022-5347(01)64913-9
  5. Wu, 1997, Loss of imprinting and overexpression of IGF2 gene in gastric adenocarcinoma., Cancer Lett, 120, 9, 10.1016/S0304-3835(97)00279-6 · doi:10.1016/s0304-3835(97)00279-6
  6. Werner, 1993, The regulation of insulin-like growth factor-I receptor gene expression by positive and negative zinc-finger transcription factors., Adv Exp Med Biol, 343, 91, 10.1007/978-1-4615-2988-0_10 · doi:10.1007/978-1-4615-2988-0_10
  7. Okamoto, 1990, Insulin-like growth factor-II/mannose-6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose-6-phosphate, but capable in response to insulin-like growth factor-II., Biochem Biophys Res Commun, 168, 1201, 10.1016/0006-291X(90)91156-M · doi:10.1016/0006-291x(90)91156-m
  8. Varga, 1999, Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities., Proc Natl Acad Sci USA, 96, 692, 10.1073/pnas.96.2.692 · doi:10.1073/pnas.96.2.692
  9. Csernus, 1999, Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro., Proc Natl Acad Sci USA, 96, 3098, 10.1073/pnas.96.6.3098 · doi:10.1073/pnas.96.6.3098
  10. Pollak, 1998, Mechanism of antineoplastic action of somatostatin analogs., Proc Soc Exp Biol Med, 217, 143, 10.3181/00379727-217-44216 · doi:10.3181/00379727-217-44216
  11. Antoniades, 1992, Expression of insulin-like growth factors-I and II and their receptor mRNAs in primary human astrocytomas and meningiomas: in vivo studies using in situ hybridization and immunocytochemistry., Int J Cancer, 50, 215, 10.1002/ijc.2910500210 · doi:10.1002/ijc.2910500210
  12. Sandberg-Nordqvist, 1993, Characterization of insulin-like growth factor-I in human primary brain tumors., Cancer Res, 53, 2475
  13. Hirano, 1999, Insulin-like growth factor-I content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas, Neurooncology, 1, 109
  14. Lichtor, 1993, Expression of insulin-like growth factors and their receptors in human meningiomas., J Neurooncol, 17, 183, 10.1007/BF01049974 · doi:10.1007/bf01049974
  15. Hultberg, 1993, Gene expression of insulin-like growth factor-II in human intracranial meningioma., Cancer, 72, 3282, 10.1002/1097-0142(19931201)72:11<3282::AID-CNCR2820721125>3.0.CO;2-N · doi:10.1002/1097-0142(19931201)72:11<3282::aid-cncr2820721125>3.0.co;2-n
  16. Sara, 1986, Enhancement of insulin-like growth factor-II receptors in glioblastomas., Cancer Lett, 32, 229, 10.1016/0304-3835(86)90174-6 · doi:10.1016/0304-3835(86)90174-6
  17. Gammeltoft, 1988, Expression of two types of receptors for insulin-like growth factors in human glioma., Cancer Res, 48, 1233
  18. Glick, 1989, Insulin and insulin-like growth factor-I in brain tumors: binding and in vitro effects., Neurosurgery, 24, 791, 10.1227/00006123-198906000-00001 · doi:10.1227/00006123-198906000-00001
  19. Burgaud, 1995, Mutant IGF-I receptors as dominant negatives for growth and transformation., Biochem Biophys Res Commun, 214, 475, 10.1006/bbrc.1995.2311 · doi:10.1006/bbrc.1995.2311
  20. Resnicoff, 1996, Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor-I receptor antisense mRNA., Cancer Immunol Immunother, 42, 64, 10.1007/s002620050252 · doi:10.1007/s002620050252
  21. D’Ambrosio, 1996, A soluble insulin-like growth factor-I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis., Cancer Res, 56, 4013
  22. Resnicoff, 1994, Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors., Cancer Res, 54, 2218
  23. Lichtor, 1991, Differential expression of insulin-like growth factor-II in human meningiomas., Neurosurgery, 29, 405, 10.1227/00006123-199109000-00011 · doi:10.1227/00006123-199109000-00011
  24. Sandberg-Nordqvist, 1997, A high ratio of insulin-like growth factor-II/IGFBP-2 mRNA as a marker for anaplasia in meningiomas., Cancer Res, 57, 2611
  25. Kurihara, 1989, Characterization of insulin-like growth factor-I and epidermal growth factor receptors in meningioma., J Neurosurg, 71, 538, 10.3171/jns.1989.71.4.0538 · doi:10.3171/jns.1989.71.4.0538
  26. Tsutsumi, 1994, Effect of suramin on 125I-IGF-I binding to human meningiomas and on proliferation of meningioma cells., J Neurosurg, 80, 502, 10.3171/jns.1994.80.3.0502 · doi:10.3171/jns.1994.80.3.0502
  27. Friend, 1999, Growth hormone receptor expression and function in meningioma: effect of a specific receptor antagonist., J Neurosurg, 91, 93, 10.3171/jns.1999.91.1.0093 · doi:10.3171/jns.1999.91.1.0093
  28. McCutcheon, J Neurosurg, 92, 306, 10.3171/jns.2000.92.2.0306 · doi:10.3171/jns.2000.92.2.0306
  29. Tricoli, 1986, Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas., Cancer Res, 46, 6169
  30. Culouscou, 1987, Simultaneous production of insulin-like growth factor-I and epidermal growth factor competing growth factors by HT-29 human colon cancer line., Int J Cancer, 40, 646, 10.1002/ijc.2910400513 · doi:10.1002/ijc.2910400513
  31. Lambert, 1990, Abnormal expression and structural modification of the of insulin-like growth factor-II gene in human colorectal tumors., Int J Cancer, 46, 405, 10.1002/ijc.2910460313 · doi:10.1002/ijc.2910460313
  32. Zarrilli, 1994, Expression of insulin-like growth factor-II and IGF-I receptor during proliferation and differentiation of CaCo-2 human colon carcinoma cells., Cell Growth Diff, 5, 1085
  33. Guo, 1995, Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions., J Am Coll Surg, 181, 145
  34. Kawamoto, 1998, Expression of insulin-like growth factor-II can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival., Oncology, 55, 242, 10.1159/000011858 · doi:10.1159/000011858
  35. Kawamoto, 1999, Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastasis from colorectal carcinoma., Cancer, 85, 18, 10.1002/(SICI)1097-0142(19990101)85:1<18::AID-CNCR3>3.0.CO;2-4 · doi:10.1002/(sici)1097-0142(19990101)85:1<18::aid-cncr3>3.0.co;2-4
  36. Rouyer-Fessard, 1990, Expression of two types of receptor for insulin-like growth factors in human colonic epithelium., Gastroenterology, 98, 703, 10.1016/0016-5085(90)90291-8 · doi:10.1016/0016-5085(90)90291-8
  37. Adenis, 1995, Type I insulin-like growth factor receptors in human colorectal cancer, Eur J Cancer, 31A, 50, 10.1016/0959-8049(94)00368-F · doi:10.1016/0959-8049(94)00368-f
  38. Singh, 1994, Episomal expression of sense and antisense insulin-like growth factor (IGF) binding protein-4 complimentary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) by mechanisms that are independent of and dependent upon IGF-I., Cancer Res, 54, 6563
  39. Macdonald, 1999, Growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2, by constitutive expression of insulin-like growth factor binding protein-3., J Gastroenterol Hepatol, 14, 72, 10.1046/j.1440-1746.1999.01803.x · doi:10.1046/j.1440-1746.1999.01803.x
  40. Qin, 1991, Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats., Int J Cancer, 47, 765, 10.1002/ijc.2910470524 · doi:10.1002/ijc.2910470524
  41. Alonso, 1992, Effects of pentagastrin and of the somatostatin analogue (SMS 201–995) on growth of CT26 in vivo adenocarcinoma of the colon., Surg Gynecol Obstet, 175, 441
  42. Qin, 1992, Treatment of liver metastasis of human colon cancers in nude mice with somatostatin analogue RC-160., Int J Cancer, 52, 791, 10.1002/ijc.2910520520 · doi:10.1002/ijc.2910520520
  43. Glass, 1994, Serum concentrations of insulin-like growth factor-I in colonic neoplasia., Acta Oncol, 33, 70, 10.3109/02841869409098380 · doi:10.3109/02841869409098380
  44. Iftikhar, 1991, The effect of long-acting somatostatin analogue SMS 201–995 therapy on tumor kinetic measurements and serum tumor marker concentrations in primary rectal cancer., Br J Cancer, 63, 971, 10.1038/bjc.1991.212 · doi:10.1038/bjc.1991.212
  45. Cascinu, 1995, A randomized trial of octreotide vs. best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy., Br J Cancer, 71, 97, 10.1038/bjc.1995.19 · doi:10.1038/bjc.1995.19
  46. Goldberg, 1995, A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma., Cancer, 76, 961, 10.1002/1097-0142(19950915)76:6<961::AID-CNCR2820760608>3.0.CO;2-A · doi:10.1002/1097-0142(19950915)76:6<961::aid-cncr2820760608>3.0.co;2-a
  47. Cascinu, 1997, Inhibition of tumor cell kinetics and serum insulin-like growth factor-I levels by octreotide in colorectal cancer patients., Gastroenterology, 113, 767, 10.1016/S0016-5085(97)70170-7 · doi:10.1016/s0016-5085(97)70170-7
  48. Guo, 1993, Insulin-like growth factor binding protein modulates the growth response to insulin-like growth factor-I by human gastric cancer cells., Gastroenterology, 104, 1595, 10.1016/0016-5085(93)90634-O · doi:10.1016/0016-5085(93)90634-o
  49. Ohmura, 1990, Insulin-like growth factor-I and transforming growth factor α as autocrine growth factors in human pancreatic cancer cell growth., Cancer Res, 50, 103
  50. Oku, 1991, Effects of various growth factors on growth of a cloned human esophageal squamous cancer cell line in a protein-free medium., Anticancer Res, 11, 1591
  51. Chen, 1991, Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells., Cancer Res, 51, 1898
  52. D’Errico, 1994, Expression of insulin-like growth factor-II in human hepatocellular carcinomas: an immunohistochemical study., Path Intl, 44, 131, 10.1111/j.1440-1827.1994.tb01697.x · doi:10.1111/j.1440-1827.1994.tb01697.x
  53. Sohda, 1997, Co-localization of insulin-like growth factor-II and the proliferation marker MIB1 in hepatocellular carcinoma cells., J Clin Pathol, 50, 135, 10.1136/jcp.50.2.135 · doi:10.1136/jcp.50.2.135
  54. Minuto, 1986, Evidence for an increased somatomedin-C/insulin-like growth factor-I content in primary human lung tumors., Cancer Res, 46, 985
  55. Minuto, 1988, Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor-I on an established human lung cancer cell line., Cancer Res, 46, 3716
  56. Jaques, 1988, Production of immunoreactive insulin-like growth factor-I and response to exogenous IGF-I in small cell lung cancer cell lines., Exp Cell Res, 176, 336, 10.1016/0014-4827(88)90335-7 · doi:10.1016/0014-4827(88)90335-7
  57. Macaulay, 1990, Autocrine function for insulin-like growth factor-I in human small cell lung cancer cell lines and fresh tumor cells., Cancer Res, 50, 2511
  58. Reeve, 1990, Production of immunoreactive insulin-like growth factor (IGF)-I and IGF binding proteins by human lung tumors., Br J Cancer, 61, 727, 10.1038/bjc.1990.163 · doi:10.1038/bjc.1990.163
  59. Schardt, 1993, Characterization of insulin-like growth factor-II receptors in human small cell lung cancer cell lines., Exp Cell Res, 204, 22, 10.1006/excr.1993.1004 · doi:10.1006/excr.1993.1004
  60. Zia, 1996, Monoclonal antibody αIR3 inhibits non-small cell lung cancer growth in vitro and in vivo., J Cell Biochem Suppl, 24, 269, 10.1002/jcb.240630522 · doi:10.1002/jcb.240630522
  61. Lee, 1996, Antitumor effects of an adenovirus expressing antisense insulin-like growth factor-I receptor on human lung cancer cell lines., Cancer Res, 56, 3038
  62. Long, 1998, Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type I IGF receptor., Exp Cell Res, 238, 116, 10.1006/excr.1997.3814 · doi:10.1006/excr.1997.3814
  63. Taylor, 1988, In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue., Biochem Biophys Res Commun, 153, 81, 10.1016/S0006-291X(88)81192-6 · doi:10.1016/s0006-291x(88)81192-6
  64. Bogden, 1990, Response of human lung tumor xenografts with a somatostatin analogue (Somatuline)., Cancer Res, 50, 4360
  65. Pinski, 1994, Effects of somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice., Br J Cancer, 70, 886, 10.1038/bjc.1994.415 · doi:10.1038/bjc.1994.415
  66. Macaulay, 1991, Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer., Br J Cancer, 64, 451, 10.1038/bjc.1991.330 · doi:10.1038/bjc.1991.330
  67. Cotto, 1994, Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma., Ann Oncol, 5, 290, 10.1093/oxfordjournals.annonc.a058812 · doi:10.1093/oxfordjournals.annonc.a058812
  68. Marschke Jr, 1999, Phase II study of high dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer., Am J Clin Oncol, 22, 15, 10.1097/00000421-199902000-00004 · doi:10.1097/00000421-199902000-00004
  69. Minuto, 1989, Immunoreactive insulin-like growth factor (IGF)-I and IGF binding protein content in human thyroid tissue., J Clin Endocrinol Metab, 68, 621, 10.1210/jcem-68-3-621 · doi:10.1210/jcem-68-3-621
  70. Onoda, 1992, Autocrine role of insulin-like growth factor-I in a human thyroid cancer cell line, Eur J Cancer, 28A, 1904, 10.1016/0959-8049(92)90033-X · doi:10.1016/0959-8049(92)90033-x
  71. Yashiro, 1989, Expression of insulin-like growth factor receptors in primary human thyroid neoplasms., Acta Endocrinol (Copenh), 121, 112, 10.1530/acta.0.1210112 · doi:10.1530/acta.0.1210112
  72. Gebauer, 1998, mRNA expression of the components of the insulin-like growth factor system in breast cancer cell lines, tissues and metastatic breast cancer cells., Anticancer Res, 18, 1191
  73. De Leon, 1988, Demonstration of insulin-like growth factor (IGF)-I and IGF-II receptors and binding protein in human breast cancer cell lines., Biochem Biophys Res Commun, 152, 398, 10.1016/S0006-291X(88)80727-7 · doi:10.1016/s0006-291x(88)80727-7
  74. Clemmons, 1990, Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status., Endocrinology, 127, 2679, 10.1210/endo-127-6-2679 · doi:10.1210/endo-127-6-2679
  75. Pratt, 1994, Insulin-like growth factor binding protein-3 (IGFBP-3) inhibits estrogen-stimulated breast cancer cell proliferation., Biochem Biomed Res Commun, 198, 292, 10.1006/bbrc.1994.1041 · doi:10.1006/bbrc.1994.1041
  76. Nickerson, 1997, Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells., Biochem Biomed Res Commun, 237, 690, 10.1006/bbrc.1997.7089 · doi:10.1006/bbrc.1997.7089
  77. Martin, 1995, Insulin-like growth factor binding protein 3 (IGFBP-3) production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol., Endocrinology, 136, 1219, 10.1210/endo.136.3.7532580 · doi:10.1210/endo.136.3.7532580
  78. Van den Berg, 1997, Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice., Eur J Cancer, 33, 1108, 10.1016/S0959-8049(97)00071-3 · doi:10.1016/s0959-8049(97)00071-3
  79. Rohlik, 1987, An antibody to the receptor for insulin-like growth factor receptor-I inhibits the growth of MCF-7 cells in tissue culture., Biochem Biophys Res Commun, 149, 276, 10.1016/0006-291X(87)91635-4 · doi:10.1016/0006-291x(87)91635-4
  80. De Leon, 1992, Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells., Growth Factors, 6, 327, 10.3109/08977199209021544 · doi:10.3109/08977199209021544
  81. Vennin, 1989, Effect of the long acting somatostatin analogue SMS 201–995 (Sandostatin) in advanced breast cancer., Anticancer Res, 9, 153
  82. Di Leo, 1995, Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue in the treatment of advanced breast cancer., Breast Cancer Res Treat, 34, 237, 10.1007/BF00689715 · doi:10.1007/bf00689715
  83. Canobbio, 1995, Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I levels., Anticancer Res, 15, 2687
  84. O’Byrne, 1999, Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer., Br J Cancer, 79, 1413, 10.1038/sj.bjc.6690226 · doi:10.1038/sj.bjc.6690226
  85. Ingle, 1999, A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma., Cancer, 85, 1284, 10.1002/(SICI)1097-0142(19990315)85:6<1284::AID-CNCR10>3.0.CO;2-P · DOI
  86. Yee, 1991, Expression of insulin-like growth factor-I, its binding proteins, and its receptors in ovarian cancer., Cancer Res, 51, 5107
  87. Resnicoff, 1993, Insulin-like growth factor-I and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines., Lab Invest, 69, 756
  88. Krywicki, 1993, Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen, Eur J Cancer, 29A, 2015, 10.1016/0959-8049(93)90464-Q · doi:10.1016/0959-8049(93)90464-q
  89. Kanety, 1996, Increased insulin-like growth factor binding protein 2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid., Br J Cancer, 73, 1069, 10.1038/bjc.1996.206 · doi:10.1038/bjc.1996.206
  90. Muller, 1998, Antisense phophorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor-I receptor in ovarian cancer cells., Int J Cancer, 77, 567, 10.1002/(SICI)1097-0215(19980812)77:4<567::AID-IJC16>3.0.CO;2-3 · doi:10.1002/(sici)1097-0215(19980812)77:4<567::aid-ijc16>3.0.co;2-3
  91. Klienman, 1993, Regulation of endometrial cancer cell growth by insulin-like growth factors and the leutinizing hormone-releasing hormone antagonist SB-75., Regul Pept, 48, 91, 10.1016/0167-0115(93)90338-9 · doi:10.1016/0167-0115(93)90338-9
  92. Hana, 1994, Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line., Endocrinology, 135, 2511, 10.1210/endo.135.6.7527333 · doi:10.1210/endo.135.6.7527333
  93. Elkas, 1998, The effects of tamoxifen on endometrial insulin-like growth factor-I expression., Obstet Gynecol, 91, 45, 10.1016/S0029-7844(97)00549-8 · doi:10.1016/s0029-7844(97)00549-8
  94. Talavera, 1990, Insulin-like growth factor-I receptors in normal and neoplastic human endometrium., Cancer Res, 50, 3019
  95. Kleinman, 1995, Modulation of insulin-like growth factor-I (IGF-I) receptors and membrane associated IGF-binding proteins in endometrial cancer cells by estradiol., Endocrinology, 136, 2531, 10.1210/endo.136.6.7750475 · doi:10.1210/endo.136.6.7750475
  96. Pearl, 1993, Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC-1-A and KLE., Gynecol Oncol, 49, 325, 10.1006/gyno.1993.1134 · doi:10.1006/gyno.1993.1134
  97. Steller, 1996, Overexpression of insulin-like growth factor-I receptor and autocrine stimulation in human cervical cancer cells., Cancer Res, 56, 1761
  98. Kaicer, 1991, Insulin-like growth factor-I and IGFBPs: stimulatory and inhibitory factors secreted by human prostate adenocarcinoma cells., Growth Factors, 4, 231, 10.3109/08977199109104819 · doi:10.3109/08977199109104819
  99. Connolly, 1994, Regulation of DU 145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop., Prostate, 24, 167, 10.1002/pros.2990240402 · doi:10.1002/pros.2990240402
  100. Lamharzi, 1998, Growth hormone-releasing hormone antagonist MZ-5–156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor-II in tumors., Proc Natl Acad Sci USA, 95, 8864, 10.1073/pnas.95.15.8864 · doi:10.1073/pnas.95.15.8864
  101. Figueroa, 1995, Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop., J Clin Endocrinol Metab, 80, 3476, 10.1210/jcem.80.12.8530586 · doi:10.1210/jcem.80.12.8530586
  102. Schally, 1987, Somatostatin analogs as adjuncts to agonists of leutinizing hormone-releasing hormone in the treatment of experimental prostate cancer., Proc Natl Acad Sci USA, 84, 7275, 10.1073/pnas.84.20.7275 · doi:10.1073/pnas.84.20.7275
  103. Pinski, 1993, Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate cancer xenografts in nude mice., Int J Cancer, 55, 963, 10.1002/ijc.2910550615 · doi:10.1002/ijc.2910550615
  104. Pinski, 1993, Somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice., Cancer Lett, 71, 189, 10.1016/0304-3835(93)90115-P · doi:10.1016/0304-3835(93)90115-p
  105. Jungwirth, 1997, Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone., Br J Cancer, 75, 1585, 10.1038/bjc.1997.271 · doi:10.1038/bjc.1997.271
  106. Parmar, 1992, Therapeutic response to somatostatin analogue BIM 23014 in metastatic prostate cancer., Clin Exp Metastasis, 10, 3, 10.1007/BF00163570 · doi:10.1007/bf00163570
  107. Figg, 1995, A phase I study of the somatostatin analogue somatuline in patients with metatstatic hormone-refractory prostate cancer., Cancer, 75, 2159, 10.1002/1097-0142(19950415)75:8<2159::AID-CNCR2820750820>3.0.CO;2-O · doi:10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o
  108. Maulard, 1995, Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer., Cancer Chemother Pharmacol, 36, 259, 10.1007/BF00685857 · doi:10.1007/bf00685857
  109. Weima, 1989, Human teratocarcinoma cells express functional insulin-like growth factor-I receptors., Exp Cell Res, 184, 427, 10.1016/0014-4827(89)90341-8 · doi:10.1016/0014-4827(89)90341-8
  110. Jungwirth, 1997, Growth hormone-releasing hormone antagonist MZ-4–71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma., Proc Natl Acad Sci USA, 94, 5810, 10.1073/pnas.94.11.5810 · DOI
  111. Pinski, 1996, Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice., Int J Cancer, 65, 870, 10.1002/(SICI)1097-0215(19960315)65:6<870::AID-IJC27>3.0.CO;2-6 · doi:10.1002/(sici)1097-0215(19960315)65:6<870::aid-ijc27>3.0.co;2-6
  112. Foley Jr, 1982, Demonstration of receptors for insulin and insulin-like growth factors on Swarm rat chondrosarcoma chondrocytes., J Biol Chem, 25, 663, 10.1016/S0021-9258(19)68244-X · doi:10.1016/s0021-9258(19)68244-x
  113. Seong, 1994, Insulin-like growth factor-I regulation of Swarm rat chondrosarcoma chondrocytes in culture., Exp Cell Res, 211, 238, 10.1006/excr.1994.1083 · doi:10.1006/excr.1994.1083
  114. Neely, 1991, Insulin-like growth factors are mitogenic for human keratinocytes and a squamous cell carcinoma, J Invest Dermatol, 96, 104, 10.1111/1523-1747.ep12515914 · doi:10.1111/1523-1747.ep12515914
  115. Wilker, 1999, Enhancement of susceptibility to diverse skin tumor promoters by activation of insulin-like growth factor-I receptor in the epidermis of transgenic mice., Mol Carcinog, 25, 122, 10.1002/(SICI)1098-2744(199906)25:2<122::AID-MC7>3.0.CO;2-8 · doi:10.1002/(sici)1098-2744(199906)25:2<122::aid-mc7>3.0.co;2-8
  116. Vetter, 1986, Human leukemic cells: receptor binding and biological effects of insulin and insulin-like growth factors., Leukemia Res, 10, 1201, 10.1016/0145-2126(86)90238-9 · doi:10.1016/0145-2126(86)90238-9
  117. Pepe, 1987, Receptor binding and mitogenic effects of insulin and insulin-like growth factor-I and II for human myeloid leukemic cells., J Cell Physiol, 133, 219, 10.1002/jcp.1041330204 · DOI
  118. Sinclair, 1988, Effects of insulin and insulin-like growth factor-I on growth of human leukemia cells in serum-free and protein-free medium., Blood, 72, 66, 10.1182/blood.V72.1.66.66 · doi:10.1182/blood.v72.1.66.66
  119. Estrov, 1991, Human growth hormone and insulin-like growth factor-I enhance the proliferation of human leukemic blasts., J Clin Oncol, 9, 394, 10.1200/JCO.1991.9.3.394 · doi:10.1200/jco.1991.9.3.394
  120. Conlon, 1995, Long R-3 insulin-like growth factor-I (IGF-I) stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentration in guinea pigs., J Endocrinol, 146, 247, 10.1677/joe.0.1460247 · doi:10.1677/joe.0.1460247

Cited by

See all 843

Metadata

Authors
Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A., & Friend, K. E.
Venue
Endocrine Reviews
Published
2000-06-01
Volume
21
Issue
3
Pages
215-244
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2160835537
Cited by
843
References
139
FWCI
26.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.